BioNTech’s Oncology Push Meets Market Reality: Strong ASCO Data Can’t Mask Restructuring and Revenue Decline
05.06.2026 - 21:33:09 | boerse-global.de
The disconnect between scientific progress and market sentiment is rarely starker than in BioNTech’s current predicament. At the American Society of Clinical Oncology annual meeting, the German biotech unveiled encouraging Phase 2/3 data for its flagship oncology candidate, Pumitamig, in non-small cell lung cancer, alongside durable responses from Gotistobart in platinum-resistant ovarian cancer. Yet the stock languishes at €76.35, barely 12% above its 52-week low and 27% below the January high of €105.80.
That gap stems from a trio of structural headwinds that positive early-stage signals alone cannot offset. The most immediate is the continued erosion of BioNTech’s COVID-19 franchise. First-quarter revenue fell to €118 million, a 35% year-on-year plunge and well short of the €171 million consensus forecast. The net loss widened to €494.6 million, even as the company burned through cash while shoring up its pipeline. Full-year guidance of €2.0–2.3 billion reflects a further 20-30% drop from the €2.9 billion booked in 2025.
To adapt, BioNTech is carving out a leaner industrial footprint. It will cut roughly 1,860 positions, or 22% of its workforce, and close the manufacturing sites in Idar-Oberstein, Marburg, and TĂĽbingen by the end of 2027. Its Singapore facility is due to wind down in the first quarter of 2027. The restructuring frees up capital for oncology R&D, but it also underscores the scale of the pivot from pandemic-era blockbusters to a high-risk, high-reward cancer pipeline.
That pipeline is now the fulcrum of the investment debate. Bernstein SocGen has maintained a “Market Perform” rating and a $96 price target, warning that Pumitamig’s upcoming pivotal studies may disappoint relative to earlier data. The firm’s risk-adjusted peak sales estimates for the clinical pipeline sit 52% below the consensus — a far more skeptical view than peers such as Bank of America ($125, Buy), H.C. Wainwright ($130, Buy), and UBS ($135, Buy). The wide range reflects how little agreement exists on the commercial viability of BioNTech’s late-stage oncology assets.
Should investors sell immediately? Or is it worth buying BioNTech?
A further cloud is the planned departure of founders and co-CEOs Ugur Sahin and Ă–zlem TĂĽreci by the end of 2026. The March 2026 announcement sent the stock down 17% in a single session, and replacing visionary leaders during a critical pipeline inflection point introduces significant execution risk. The market is not yet convinced that the next generation of management can drive the same strategic clarity.
Regulatory headwinds add to the uncertainty. The U.S. government’s proposal to impose tariffs of up to 100% on imported medicines has cast a pall over the entire sector, and any trade friction would directly affect BioNTech’s ability to commercialize its oncology portfolio in its largest market.
Still, the bull case has not collapsed. BioNTech’s balance sheet remains fortress-like, with roughly €16.8 billion in cash and marketable securities, supplemented by a $1 billion share buyback authorization. That war chest provides ample runway for the 15 late-stage trials — including six new Phase 3 studies — that the company plans to run this year. The average analyst price target of €106.32 implies a 38% upside from current levels, suggesting that many in the sell-side community see the stock as deeply undervalued.
BioNTech at a turning point? This analysis reveals what investors need to know now.
The ultimate test, however, is whether Pumitamig can translate its promising Phase 2/3 data into registrational success. Until then, BioNTech remains caught between a shrinking revenue base, a leadership transition, and an oncology bet that the market demands proof of, not just promise.
Ad
BioNTech Stock: New Analysis - 5 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
